Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.

"cox regression and mixed-effect models were used for statistical analysis ( supplementary data s1 available at rheumatology online)."

"Disclosure statement : A.G. was an employee of Roche from October 2019 to October 2021 and received support from Roche for data analysis and medical writing assistance. D.K. discloses consulting fees from Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech/Roche, Horizon, Paracrine Cell Therapy, Mitsubishi Tanabe Pharma, Prometheus and Theraly; has stock options in Eicos Sciences Inc.; and is the Chief Medical Officer of Eicos Sciences Inc., a subsidiary of CiviBioPharma. C.J.F.L. was previously an employee of and owned stock in Genentech. D.E.F. discloses grants/research support from Amgen, Corbus, CSL Behring, Galapagos, Gilead, GlaxoSmithKline, Horizon, Novartis, Pfizer, Roche/Genentech and Talaris, and consulting fees from Amgen, Corbus, Galapagos, Horizon, Kadmon, Pfizer and Talaris. G.R. discloses a research grant from the National Institutes of Health for idiopathic pulmonary fibrosis studies; consulting fees from Boehringer Ingelheim, United Therapeutics, Bristol Myers Squibb and Veracyte; unpaid participation on an Avalyn safety monitoring board; unpaid participation for the Pulmonary Fibrosis Foundation steering committee and scientific advisory board; unpaid participation on a steering committee for Roche/Genentech, Biogen, Bellerophan, Nitto and Fibrogen; and is a chair for the American Thoracic Society guideline committee for idiopathic pulmonary fibrosis. F.J.M. served on the steering committee of an idiopathic pulmonary fibrosis therapeutic trial sponsored by Roche and on the steering committee of interstitial lung disease studies sponsored by Afferent/Merck, Bayer, Biogen, Nitto, Patara/Respivant, Promedior/Roche and Vercyte; discloses consulting fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Bridge Therapeutics, CSL Behring, DevPro, Genentech, IQVIA, Lung Therapeutics, Sanofi, Shionogi, twoXar and Veracyte; received speaker fees from United Therapeutics; received attendance/travel support from Boehringer Ingelheim, CSL Behring and Patara/Respivant; and participated on data safety monitoring boards or advisory boards for Biogen and Boehringer Ingelheim. M.Z. is an employee of Parexel International, which provides functional service to Roche. A.J. was an employee of Roche Pharmaceuticals at the time of the study. S.I.N. is a current employee of GlaxoSmithKline and has received grants or contracts from GlaxoSmithKline and consulting fees from Roche. C.P.D. has received research grants to his institution from Servier, Horizon, Arxx Therepeutics and GlaxoSmithKline; consulting fees from Roche, Janssen, GlaxoSmithKline, Bayer, Sanofi, Galapagos, Boehringer Ingelheim, CSL Behring, Corbus and Acceleron; and honoraria from Janssen, Boehringer Ingelheim and Corbus. S.H. has nothing to disclose."

"Funding The study was sponsored by F. Hoffmann-La Roche Ltd. This work was funded in part by The Royal Free Charity through a generous bequest for Scleroderma Research from Richard King. The sponsor was involved in study design, analysis and interpretation of data, writing the manuscript, and the decision to submit the manuscript for publication. Disclosure statement: A.G. was an employee of Roche from October 2019 to October 2021 and received support from Roche for data analysis and medical writing assistance. D.K. discloses consulting fees from Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech/Roche, Horizon, Paracrine Cell Therapy, Mitsubishi Tanabe Pharma, Prometheus and Theraly; has stock options in Eicos Sciences Inc.; and is the Chief Medical Officer of Eicos Sciences Inc., a subsidiary of CiviBioPharma. C.J.F.L. was previously an employee of and owned stock in Genentech. D.E.F. discloses grants/research support from Amgen, Corbus, CSL Behring, Galapagos, Gilead, GlaxoSmithKline, Horizon, Novartis, Pfizer, Roche/Genentech and Talaris, and consulting fees from Amgen, Corbus, Galapagos, Horizon, Kadmon, Pfizer and Talaris. G.R. discloses a research grant from the National Institutes of Health for idiopathic pulmonary fibrosis studies; consulting fees from Boehringer Ingelheim, United Therapeutics, Bristol Myers Squibb and Veracyte; unpaid participation on an Avalyn safety monitoring board; unpaid participation for the Pulmonary Fibrosis Foundation steering committee and scientific advisory board; unpaid participation on a steering committee for Roche/Genentech, Biogen, Bellerophan, Nitto and Fibrogen; and is a chair for the American Thoracic Society guideline committee for idiopathic pulmonary fibrosis. F.J.M. served on the steering committee of an idiopathic pulmonary fibrosis therapeutic trial sponsored by Roche and on the steering committee of interstitial lung disease studies sponsored by Afferent/Merck, Bayer, Biogen, Nitto, Patara/Respivant, Promedior/Roche and Vercyte; discloses consulting fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Bridge Therapeutics, CSL Behring, DevPro, Genentech, IQVIA, Lung Therapeutics, Sanofi, Shionogi, twoXar and Veracyte; received speaker fees from United Therapeutics; received attendance/travel support from Boehringer Ingelheim, CSL Behring and Patara/Respivant; and participated on data safety monitoring boards or advisory boards for Biogen and Boehringer Ingelheim. M.Z. is an employee of Parexel International, which provides functional service to Roche. A.J. was an employee of Roche Pharmaceuticals at the time of the study. S.I.N. is a current employee of GlaxoSmithKline and has received grants or contracts from GlaxoSmithKline and consulting fees from Roche. C.P.D. has received research grants to his institution from Servier, Horizon, Arxx Therepeutics and GlaxoSmithKline; consulting fees from Roche, Janssen, GlaxoSmithKline, Bayer, Sanofi, Galapagos, Boehringer Ingelheim, CSL Behring, Corbus and Acceleron; and honoraria from Janssen, Boehringer Ingelheim and Corbus. S.H. has nothing to disclose."

"Trial Registration ClinicalTrials.gov: NCT02453256."